Address the Need of Standards Development in the CGT Space: SCB & Standards Initiatives

> Jiwen Zhang, Ph.D SCB President

Executive Director, Regulatory Affairs Tmunity Therapeutics, Inc.



Outline

- CMC challenges and need of standards
- SCB and standards initiatives
- Rapid Microbiology Testing Method (RMTM) project



Unique Challenges in Cell and Gene Therapy - Manufacturing, Control, Testing (CMC)

Remarks by Commissioner Gottlieb to the Alliance for Regenerative Medicine's Annual Board Meeting, May 22, 2018

"We're at a key point when it comes to cell and gene therapy. These therapies have the potential to address hundreds, if not thousands, of different rare and common diseases. For a long time, they were largely theoretical constructs. Now they're a therapeutic reality. And it's my expectation that they will soon become the mainstay of how we treat a wide range of illness."

"In contrast to traditional drug review, where 80 percent of the review is focused on the clinical portion of that process, and maybe 20 percent is focused on the product issues, I'd say that this general principal is almost completely inverted when it comes to cell and gene therapy."

CMC Challenges – in Need of Standards

Comparison of Specifications

Products	Identity	Purity/impurity	Safety	Potency	
Gleevec	IR, HPLC,.	impurities (HPLC), residual	microbiologic	Dissolution	
(NCE)	XRPD, assay	solvents (GC), water content	al quality	(<mark>pharmacopeia</mark>)	
	(HPLC)	(KF), sulphated ash (<mark>Ph Eur</mark>)	(<mark>pharmacope</mark>		
		and heavy metals (<mark>Ph Eur</mark>);	<mark>ia</mark>)		
		methanesulphonic acid			
		content (potentiometric			
		titration)			
Kymriah	presence of	<pre># viable cells*;</pre>	Endotoxin;	CAR expression	
(Autologo	CAR19	% Viable CD19+ B cells*;	Sterility;	(potency);	
us gene-	transgene	% viable T cells*;	mycoplasma;	IFN-γ Release	
modified		Cell viability*;	Presence of		
cell		Transduction efficiency*;	VSV-G DNA		
therapy)		Residual Beads			

Role of Standards

Standards to reduce cost, streamline development, support commercialization & patient access

"Mass production became possible through standardization. By the turn of the 19th century, standardization was already recognized in industrialized countries as a powerful tool to increase productivity through interchangeability and reduction of variety.

After the First World War, standardization, through reduction in variety, was established as a useful management tool for reducing costs."


Role of standards by UNITED NATIONS INDUSTRIAL DEVELOPMENT ORGANIZATION

https://www.unido.org/fileadmin/media/documents/pdf/tcb_role_standards.pdf




From Need of Standards to SCB

C©©RDINATING




SCB Organizational Structure





SCB: Coordinate Standards Efforts From Upstream to Downstream



STANDARDS C©©RDINATING BODY

FDA Standards Development Project

SUPPORTING THE DEVELOPMENT OF STANDARDS FOR REGENERATIVE MEDICINE THERAPIES



KEY PRODUCTS



Report on the current landscape for regenerative medicine therapy standards




Three, educational webinars on standards



Report that specifies processes and criteria to identify and prioritize standards



Report that specifies processes and criteria to determine the feasibility of standards



NEXIGHT GROUP



On Track to Complete Projects By Sept



Webinars

- 1st Webinar completed December 12, 2017
- 2nd Webinar: March 13
- 3rd webinar: June 26
- Webinar recordings available on SCB website





Standards landscape report

- 194 standards identified
- Summarized by sectors, by functional areas
- Standards gaps and needs identified, eg. Cell counting, cell characterization, raw materials, sterilization and sterility testing, reference materials
 https://static1.squarespace.com/s tatic/58a331b0db29d63c7fb6452
 8/t/5a9ee032e2c483767c878be9 /1520361532848/Landscape+Rep ort 3-2-2018.pdf



ANDARDS

C©©RDINATING

Reports in progress

- Standards identification and prioritization
- Feasibility assessment
- A Roadmap to Improve Processes and Criteria to Advance Standards Needs for Regenerative Medicine

SCB Supporting Stake Holder Projects



C©©RDINATING



- Rapid microbial testing methods
- Microphysiological paper
- Characterization of fibrous scaffolds (along with ASTM, NIST, BioFabUSA)
- Pre-existing immunity standards
- ARM S&T A-gene project
- Cell transportation
- Cell therapy manufacturing equipment

• Five projects proposed

- Cell potency assays for cell therapy & tissue engineering
- Fluorescence intensity measurements in cell based assays
- Characterization for various cell types (e.g., neurons, pancreatic beta cells, cardiomyocytes)
- Cell Tracking Project (in collaboration with HESI)
- Training Programs with Northeastern University (NEU)

SCB Supporting ISO TC276

Coordinating

- Leading three standards projects
 - Rapid Microbial Testing Methods (being presented at ISO meeting June 2018)
 - Cell transportation (ISO 21973)
 - ISO 23565 TS General requirements and considerations for equipment systems used in manufacturing of cellular therapeutic products
 - Supporting **seven** standards projects
 - ISO 20391-1:2018 Cell Counting Part 1: General guidance on cell counting methods – published January 19, 2018!
 - ISO 20191-2 Cell counting Part 2
 - ISO 20395-1 Quantification methods nucleic acid qPCR & dPCR
 - ISO 23033 Cell characterization
 - ISO 20399 Technical Specifications (TS) Ancillary Materials for Cell Therapy
 - Part 1: General Requirements
 - Part 2: Best practice for suppliers
 - Part 3: Best practice for users
 - To be published late 2018!
 - SCB will be leading a new project to develop IS document by combining 3 TS documents



SCB Supporting ASTM F04

ASTM F04 Medical and Surgical Materials and Devices

- Fo4.41 Classification and Terminology for TEMPs (tissue engineered medical products)
- Fo4.42 Biomaterials and Biomolecules for TEMPs
- Fo_{4.43} Cells and Tissue Engineered Constructs for TEMPs
- Fo4.44 Assessment for TEMPs
- Fo4.45 Adventitious Agents Safety
- Fo4.46 Cell Signaling

Please contact SCB Technical Program Manager, Dawn Henke (<u>dhenke@regenmedscb.org</u>), if you would like to participate in these efforts.



RMTM Project: the Need of the CGT Field

Regulatory/FDA requirements:

- 21 CFR 610.12 Sterility Testing
- 2012 sterility rule encourages sponsors to develop and validate alternative methods

ANDARDS

©®RDINATING

Current standards testing methods:

- Pharmacopia (USP 71/EP/JP) growth method
- Limitations and gaps
 - CART products released and administered to patients before test results available

Request from Stake holders

- Rapid testing methods
- Standardized
 methods to ease
 validation
 requirements by
 individual
 sponsors

RMTM Project: SCB Addressing the Need


- June 2017: project initiation, establishing steering committee
 - Steering committee: KOLs from U. Penn, Georgia Tech, MSKCC, MIT, Celgene, CCRM, Novartis, NIST
- July 2017: responded to NIIMBL quick start project call to develop standardized RMTM
 - Overall project plan
 - Preliminary input from the FDA
 - Decision to organize a stake holder workshop
- April 10, 2018: stake holder workshop co-sponsored by SCB, NIST, BiofabUSA, and NIIMBL
 - Project roadmap
 - Initial documentary standard: risk based control and testing strategy

RMTM Project Road Map: Technology and Standards Development

 July 2017 Project initiated Project proposal & roadmap Support from stakeholders, NIST, NIIMBL, Biofab 	 1H 2018 Workshop URS for technologies Whitepaper: risk based, scenario associated guiding principles 	 2H 2018 Publish whitepaper Initiate standards projects 	 2019 & Beyond Methods validation Standards release, dissemination, adoption, education, implementation 	
 Standards Development 	 Draft documentary	 Initiate projects	 Overarching standard Compendial method	
	standards	at ISO, ASTMi	standards	
• Technology	 Specific testing m	 Commercialize testing kits New technology		
Development	products develop	development		



RMTM Standards Workstream: Risk Based Control & Testing



ISO/TC276

Risked based control & testing

• Expert support at June'18 meeting

ANDARDS

C©©RDINATING

Initiate NWIP for Dec discussion

ASTM F04

Rapid detection in biological preparations using scaffolds

- Expert support at May'18 meeting
- Drafting document for next meeting

Reference Standards

Determine, develop, & source reference standards

- Develop process
- ID resources

RMTM Technology Development Workstream

Ρ	оС	•	Devel	ор		⁄&∨	Re	elease			
Tasks		2018 Q3	2018 Q4	2019 Q1	2019 Q2	2019 Q3	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4
Agreements/hardware/Material for PoC Testing		•									
Carry out PoC Testing			-								
Write up data											
Build comprehensive URS from multiple pharma users		•		•							
Build prototype panel				-							
Preliminary testing							-				
Refinement											
Verification Testing											
Validation Testing											
Write up data											
Full Tech transfer to assay manufacture											

Engage, Participate, Contribute

For general information on the SCB, visit standardscoordinatingbody.org

For general SCB inquiries or to sign-up for regular SCB communications, contact SCB Program Manager, Allison Getz agetz@regenmedscb.org

To participate in SCB sector activities or ISO/ASTM projects, contact SCB Technical Program Manager, Dawn Henke <u>dhenke@regenmedscb.org</u>

Follow us on LinkedIn



THANK YOU!

